Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CSTI-500 is a first-in-class, orally administered new chemical entity and an optimally balanced Triple Monoamine Reuptake inhibitor (TRI). It is being investigated for the treatment for prader-willi syndrome.
Lead Product(s): CSTI-500
Therapeutic Area: Genetic Disease Product Name: CSTI-500
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2023